Xcout Intel
Shorla Pharma
Shorla Pharma (operating as Shorla Oncology) develops and commercializes innovative oncology drugs, focusing on indications where existing treatments are limited, in shortage, or inadequate. The company provides specialized cancer treatments and accessible pharmaceutical options for patients.
Subscribe to see Shorla Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Shorla Pharma at a glance
Shorla Pharma is a pharmaceuticals company headquartered in Ireland. Xcout tracks 9 named people at Shorla Pharma, including Karlijn Kroon (Chief Medical Officer).
Shorla Pharma leadership
- Karlijn KroonChief Medical Officer
- SHEILA BHATTACHARYAChief Commercial Officer
- Sharon CunninghamCEO & Co-Founder
- Orlaith RyanCTO & Co-Founder
- Maurice ClancyVice President of Research and Development
- Vincent McDermottVice President of Quality and Regulatory Affairs
3 more named people on record for Shorla Pharma, with roles, board committees and tenure — see the full roster →
Shorla Pharma competitors
A few of Shorla Pharma's closest competitors — see the full list of competitors and alternatives →
Cancer Research Horizons is a specialist drug discovery, development, and commercialisation company that translates lab-bench innovations into diagnostics and treatments for cancer patients. The company collaborates with researchers, partners, and investors to advance oncology therapeutics, manage start-ups, and license research tools and data portfolios.
Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
Deciphera Pharmaceuticals, LLC is a commercial-stage biopharmaceutical company dedicated to delivering transformational medicines, such as QINLOCK, to patients for the treatment of cancer and rare diseases.
Searchlight Pharma Inc. is a specialty pharmaceutical company headquartered in Montreal, Quebec, committed to developing and commercializing innovative healthcare products.
Servier is an international pharmaceutical company that researches, develops, and provides medical treatments primarily focused on oncology, cardio-metabolic diseases, and neurology. The company serves patients globally by delivering therapeutic innovations and advancing research in areas such as rare diseases and chronic conditions.
SciTech Development L.L.C. is a clinical-stage specialty oncology pharmaceutical company that develops safer drug delivery platforms and targeted cancer therapeutics. The company's lead candidate, ST-001 nanoFenretinide, is a patented treatment designed for lymphoma and other cancer indications.
Get Shorla Pharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Shorla Pharma in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access